tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ryffel B et al. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation. 1995 Immunopharmacology pmid:8557519
Stillman IE et al. FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model. 1995 Lab. Invest. pmid:8558840
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Shirakata Y et al. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. 1995 Transplantation pmid:8545894
Wong PY et al. FK506 in liver transplantation for chronic hepatitis B: in vitro studies on lymphocyte activation and virus replication. 1995 Liver Transpl Surg pmid:9346613
Monfar M et al. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. 1995 Mol. Cell. Biol. pmid:7528328
Echigo Y et al. Effects of cyclosporine and tacrolimus (FK 506) on acute pancreatitis in mice. 1995 Arch Surg pmid:7528496
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367
Takeda Y et al. Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. 1995 J. Cardiovasc. Pharmacol. pmid:8587392
O'Rourke M et al. Recovery of delayed-type hypersensitivity following liver transplantation. 1995 Transplant. Proc. pmid:7533369
Goodall T et al. FK506-induced endothelin release by cultured rat mesangial cells. 1995 J. Cardiovasc. Pharmacol. pmid:8587453
Gaweco AS et al. Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. 1995 Transplant. Proc. pmid:7533370
Soldin SJ Receptor (immunophilin-binding) assay for immunosuppressive drugs. 1995 Ther Drug Monit pmid:8588223
Armstrong VW et al. Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533371
Thomson AW et al. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. 1995 Ther Drug Monit pmid:8588225
Martinez OM et al. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. 1995 Transplant. Proc. pmid:7533372
Fung JJ and Starzl TE FK506 in solid organ transplantation. 1995 Ther Drug Monit pmid:8588226
Langrehr JM et al. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. 1995 Transplant. Proc. pmid:7533373
Jusko WJ Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. 1995 Ther Drug Monit pmid:8588227
Izutani H et al. Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. 1995 Transplant. Proc. pmid:7533425
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Laskow DA et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. 1995 Transplant. Proc. pmid:7533431
Shapiro R et al. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. 1995 Transplant. Proc. pmid:7533432
Winkler M et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. 1995 Transplant. Proc. pmid:7533433
Jiang H et al. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. 1995 J. Invest. Dermatol. pmid:7535825
Atkison P et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. 1995 Lancet pmid:7535875
Shaffer D et al. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). 1995 Transplantation pmid:7535958
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Sheppard KE Cyclosporin A and FK506 are potent activators of proopiomelanocortin-derived peptide secretion without affecting corticotrope glucocorticoid receptor function. 1995 J. Neuroendocrinol. pmid:8748119
Iwasaki K et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. 1995 Drug Metab. Dispos. pmid:7536652
Winkler M and Christians U A risk-benefit assessment of tacrolimus in transplantation. 1995 Drug Saf pmid:7545405
Miranker A and Karplus M An automated method for dynamic ligand design. 1995 Proteins pmid:8749844
Ockenfels HM et al. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. 1995 Arch. Dermatol. Res. pmid:7541191
Victor RG et al. Presynaptic modulation of cortical synaptic activity by calcineurin. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7541535
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
McDiarmid SV et al. The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients. 1995 J. Pediatr. Gastroenterol. Nutr. pmid:7541834
O'Gorman MA et al. Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients. 1995 Clin Transplant pmid:7579739
Kanamaru A et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. 1995 Bone Marrow Transplant. pmid:7581086
Koehler MT et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:7581088
Reisman L et al. Modulation of interleukin-1 secretion by immunosuppressive drugs, alone and in combination. 1995 Transpl. Immunol. pmid:7551978
Woo J et al. Effects of FK 506 on chimerism and the induction of donor-specific unresponsiveness following fully allogeneic bone marrow transplantation in mice. 1995 Transpl. Immunol. pmid:7551985
Kelly PA et al. Tacrolimus: a new immunosuppressive agent. 1995 Am J Health Syst Pharm pmid:7552894
Galat A and Metcalfe SM Peptidylproline cis/trans isomerases. 1995 Prog. Biophys. Mol. Biol. pmid:7538221
Goldfeld AE et al. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. 1995 Virology pmid:7538254
Jurim O et al. Living-donor liver transplantation at UCLA. 1995 Am. J. Surg. pmid:7538267
Conde M et al. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. 1995 Immunology pmid:7538492
Skeen MJ and Ziegler HK Activation of gamma delta T cells for production of IFN-gamma is mediated by bacteria via macrophage-derived cytokines IL-1 and IL-12. 1995 J. Immunol. pmid:7538532
Dollinger MM et al. Tacrolimus and cardiotoxicity in adult liver transplant recipients. 1995 Lancet pmid:7543645
Romero DF et al. Rapamycin: a bone sparing immunosuppressant? 1995 J. Bone Miner. Res. pmid:7543725
Rebollo A et al. Differential effect of rapamycin and cyclosporin A in proliferation in a murine T cell line expressing either intermediate or high affinity receptor for IL-2. 1995 Cytokine pmid:7543780
Lam E et al. Isolation of a cDNA encoding a novel human FK506-binding protein homolog containing leucine zipper and tetratricopeptide repeat motifs. 1995 Gene pmid:7543869
Minamoto A et al. Suppression of corneal graft rejection by subconjunctival injection of FK-506 in a rat model of penetrating keratoplasty. 1995 Jpn. J. Ophthalmol. pmid:7543958
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Nielsen FT et al. Nephrotoxicity of FK-506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. 1995 Nephrol. Dial. Transplant. pmid:7540737
Reichenspurner H et al. First experience with FK 506 for treatment of chronic pulmonary rejection. 1995 Transplant. Proc. pmid:7540775
Yumiba T et al. Immunosuppressive and diabetogenic effect of FK 506 on pancreatic islet xenotransplantation. 1995 Transplant. Proc. pmid:7540780
Horne SM and Young KD Escherichia coli and other species of the Enterobacteriaceae encode a protein similar to the family of Mip-like FK506-binding proteins. 1995 Arch. Microbiol. pmid:7540828
Teutsch M et al. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin. 1995 Int. Immunol. pmid:7540861
Han CW et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. 1995 Bone Marrow Transplant. pmid:7545487
Hattori Y and Nakanishi N Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages. 1995 Cell. Immunol. pmid:7545550
Han JW et al. Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. 1995 J. Biol. Chem. pmid:7545671
Ruff VA and Leach KL Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. 1995 J. Biol. Chem. pmid:7545680
Matsuo S and Okamoto K Enhancement of FK-506 activities by ganglioside (GM3) in vivo. 1995 Life Sci. pmid:7545772
Ma J et al. Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. 1995 Biophys. J. pmid:8599646
Lake KD and Canafax DM Important interactions of drugs with immunosuppressive agents used in transplant recipients. 1995 J. Antimicrob. Chemother. pmid:8601538
Díaz M et al. [Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)]. 1995 Apr-Jun Rev Med Univ Navarra pmid:7569553
Hisatomi K et al. Effect of dose of cyclosporine or FK506 and antithrombotic agents on cardiac allograft vascular disease in heterotopically transplanted hearts in rats. 1995 Jan-Feb J. Heart Lung Transplant. pmid:7537098
Díaz M et al. [Tacrolimus (FK 506): immunosuppressive alternative to solid organ transplant (Part 1)]. 1995 Jan-Mar Rev Med Univ Navarra pmid:14735715
Kawahara K et al. Effects of deoxyspergualin on bronchial anastomosis healing in canine pulmonary allografts. 1995 Jul-Aug J. Heart Lung Transplant. pmid:7578196
Motoyama K et al. Pretransplant intrathymic inoculation of donor antigen combined with FK506 treatment: prolongation of survival of cardiac, but not renal, allografts in rats. 1995 Mar-Apr World J Surg pmid:7538717
Okudaira H et al. Enhanced production and gene expression of interleukin-5 in patients with bronchial asthma: possible management of atopic diseases by down-regulation of interleukin-5 gene transcription. 1995 May-Jun Int. Arch. Allergy Immunol. pmid:7542077
Su Q et al. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. 1995 May-Jun Ren. Physiol. Biochem. pmid:7542793
Hayashi S et al. Evidence that donor pretreatment with FK506 has a synergistic effect on graft prolongation in hamster-to-rat heart xenotransplantation. 1995 May-Jun J. Heart Lung Transplant. pmid:7544621
Castillo Lugo JA Clinical and experimental immunosuppression. 1995 May-Jun Bol Asoc Med P R pmid:8573248
Seifeldin R Drug interactions in transplantation. 1995 Nov-Dec Clin Ther pmid:8750397
Schreiber SL and Crabtree GR Immunophilins, ligands, and the control of signal transduction. 1995-1996 Harvey Lect. pmid:9127988
Regazzi MB et al. Interaction between FK 506 and diltiazem in an animal model. 1996 Transplant. Proc. pmid:8623215
Hashikura Y et al. Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation. 1996 Transplant. Proc. pmid:8623218
Tomikawa S et al. Immunosuppressive effects of bactobolamine in vitro and in vivo. 1996 Transplant. Proc. pmid:8623223
Craescu CT et al. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. 1996 Biochemistry pmid:8780506
Singh N and Yu VL Prophylaxis for cytomegalovirus disease after liver transplant. 1996 Clin. Infect. Dis. pmid:8783744
Ronchetti F et al. Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907950
Costa A et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. 1996 Transplant. Proc. pmid:8907957
Ichinari H et al. Effects of portal venous inoculation with donor splenocytes on lung allograft survival in dogs. 1996 J. Thorac. Cardiovasc. Surg. pmid:8751494
Sunyecz JA et al. Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506. 1996 Gynecol. Oncol. pmid:8751565
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Yoshida Y et al. Effect of lipoprostaglandin E1 in concordant xenografts. 1996 Transplant. Proc. pmid:8658716
Kawauchi M et al. Which are the target vessels of xeno- and allo-lung rejection?--a primate single lung transplantation study. 1996 Transplant. Proc. pmid:8658719
Sakimoto H et al. Administration of tacrolimus (FK506) in hamster-to-rat pancreas xenotransplantation. 1996 Transplant. Proc. pmid:8658727
Cai W et al. Transcription-modulating drugs: mechanism and selectivity. 1996 Curr. Opin. Biotechnol. pmid:8939643
Freiberg RA et al. Specific triggering of the Fas signal transduction pathway in normal human keratinocytes. 1996 J. Biol. Chem. pmid:8940187
Poon M et al. Rapamycin inhibits vascular smooth muscle cell migration. 1996 J. Clin. Invest. pmid:8941644
Halloran PF Molecular mechanisms of new immunosuppressants. 1996 Clin Transplant pmid:8680047
Luan S et al. Molecular characterization of a FKBP-type immunophilin from higher plants. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8692927
Small SL et al. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) 1996 Ann. Neurol. pmid:8871576
Stempfle HU [Osteoporosis following heart transplantation. Pathogenesis and therapy]. 1996 Dtsch. Med. Wochenschr. pmid:8846757
Sadakane Y and Nakashima H Light-induced phase shifting of the circadian conidiation rhythm is inhibited by calmodulin antagonists in Neurospora crassa. 1996 J. Biol. Rhythms pmid:8872595
Akashi T et al. Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography. 1996 J Pharm Biomed Anal pmid:8851758
Vilquin JT et al. Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation. 1996 J. Cell Biol. pmid:8601607
Schuetz EG et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. 1996 Mol. Pharmacol. pmid:8632764